ANDREW J DANNENBERG, MD
Osteopathic Medicine at 68 St, New York, NY
License number
New York 156634
Category
Osteopathic Medicine
Type
Internal Medicine
License number
New York 156634
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
525 E 68Th St #J-314, New York, NY 10021
Phone
(212) 746-1339
(212) 746-3426 (Fax)
(212) 746-0373
(212) 746-7481 (Fax)
(212) 746-3426 (Fax)
(212) 746-0373
(212) 746-7481 (Fax)
Personal information
See more information about ANDREW J DANNENBERG at radaris.comName
Address
Phone
7 Gracie Sq, New York, NY 10028
525 68 At York, New York, NY 10001
525 68Th St, New York, NY 10001
7 Gracie Sq, New York, NY 10028
7 Gracie Ter, New York, NY 10028
Organization information
See more information about ANDREW J DANNENBERG at bizstanding.comAndrew J Dannenberg MD
525 E 68 St, New York, NY 10065
Industry:
Medical Doctor's Office
Phone:
(212) 746-4403 (Phone)
Medical Doctor, Principal:
Andrew J. Dannenberg (Medical Doctor, Principal)
Categories:
Internal Medicine Physicians & Surgeons, Physicians & Surgeons
Andrew J Dannenberg MD
7 Gracie Sq, New York, NY 10028
Industry:
Medical Doctor's Office
Principal:
Andrew J. Dannenberg (Principal)
Professional information
Andrew J Dannenberg, New York NY
Specialties:
Gastroenterologist
Address:
520 E 70Th St, New York, NY 10021
525 E 68Th St, New York, NY 10065
525 E 68Th St, New York, NY 10065
Education:
Washington University, School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine)
Treating Inflammatory Liver Disorders By Enterally Administering A Fat-Containing Diet Low In Polyunsaturated Fats
US Patent:
5622991, Apr 22, 1997
Filed:
Aug 30, 1994
Appl. No.:
8/297863
Inventors:
Andrew J. Dannenberg - New York NY
Amin A. Nanji - Wellesley MA
Amin A. Nanji - Wellesley MA
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
New England Deaconess Hospital Corp. - Boston MA
New England Deaconess Hospital Corp. - Boston MA
International Classification:
A01N 3700
US Classification:
514558
Abstract:
An enteral diet containing fat in an amount to provide from 20 to 50% of total calories, said fat containing less than 15% polyunsaturated fat (e. g. , palm oil or medium chain triglycerides) is administered to mediate amelioration of the inflammation associated with the inflammatory liver, pancreatic and intestinal disorders, e. g. , to promote healing of the liver in alcoholic hepatitis.
Cyclooxygenase-2 Inhibition
US Patent:
7041694, May 9, 2006
Filed:
Dec 7, 1998
Appl. No.:
09/554604
Inventors:
Andrew J. Dannenberg - New York NY, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
A61K 31/415, A61K 31/425
US Classification:
514395, 514370, 514372
Abstract:
Selective inhibitors of cyclooxygenase-2 are used to treat liver disease and in combination with anti-viral drugs to treat virus-caused liver disorders. Selective inhibitors of cyclooxygenase-2 which also inhibit the synthesis of cyclooxygenase-2 improve over the efficacy of conventional selective inhibitors of cyclooxygenase-2 in the treatment of inflammatory conditions, Alzheimer's disease and cancer.
Crown-Like Structures As A Biomarker For Cancer Risk And Cancer Prognosis
US Patent:
2013032, Dec 5, 2013
Filed:
Feb 11, 2012
Appl. No.:
13/984939
Inventors:
Andrew J. Dannenberg - New York NY, US
Kotha Subbaramaiah - New Hyde Park NY, US
Clifford Hudis - New York NY, US
Kotha Subbaramaiah - New Hyde Park NY, US
Clifford Hudis - New York NY, US
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER - New York NY
CORNELL UNIVERSITY - Ithaca NY
CORNELL UNIVERSITY - Ithaca NY
International Classification:
G01N 33/50
US Classification:
514733, 435 723, 435 25
Abstract:
Chronic inflammation increases the risk of several epithelial malignancies. The present invention provides methods for determining cancer risk in a patient which comprises detecting the presence of crown-like structures (CLS), methods for treating cancer associated with CLS presence, methods for determining cancer risk in a patient by quantifying the number of CLS in a sample of adipose tissue of the patient, methods of determining prognosis of a patient with breast cancer or other cancers by detecting CLS, and screening methods for anti-cancer agents or agents that inhibit or reduce CLS formation or consequences thereof.
Inhibition Of Cyclooxygenase-2 Activity
US Patent:
2009015, Jun 18, 2009
Filed:
Feb 19, 2009
Appl. No.:
12/388609
Inventors:
Andrew J. Dannenberg - New York NY, US
George Muller - Bridgewater NJ, US
George Muller - Bridgewater NJ, US
International Classification:
A61K 31/454
US Classification:
514323
Abstract:
The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are known to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed.
Inhibition Of Cyclooxygenase-2Activity
US Patent:
2002002, Feb 21, 2002
Filed:
Mar 30, 2001
Appl. No.:
09/823057
Inventors:
Andrew Dannenberg - New York NY, US
George Muller - Bridgewater NJ, US
George Muller - Bridgewater NJ, US
International Classification:
A61K031/5377, A61K031/454
US Classification:
514/235200, 514/235500, 514/323000, 514/326000
Abstract:
The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are know to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed.
Pge-M As A Biomarker Of Pulmonary Inflammation
US Patent:
2006026, Nov 23, 2006
Filed:
May 17, 2005
Appl. No.:
11/130962
Inventors:
Andrew Dannenberg - New York NY, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
G01N 33/50
US Classification:
436063000
Abstract:
Abstract of the DisclosureThe invention provides a method of, and a kit for, assessing a pulmonary abnormality in a human by providing a standard that relates a degree of pulmonary abnormality with a level of a prostaglandin Emetabolite, determining the level of the prostaglandin E metabolite in a human, and comparing the level determined in the human to the standard whereby the pulmonary abnormality in the human is assessed.
Inhibition Of Cyclooxygenase-2 Activity
US Patent:
2006019, Sep 7, 2006
Filed:
May 4, 2006
Appl. No.:
11/429300
Inventors:
Andrew Dannenberg - New York NY, US
George Muller - Bridgewater NJ, US
George Muller - Bridgewater NJ, US
International Classification:
A61K 31/5377, A61K 31/454
US Classification:
514235200, 514323000, 514326000
Abstract:
The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are known to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed.
Treatment Of Newborn Jaundice
US Patent:
5589504, Dec 31, 1996
Filed:
Jul 26, 1994
Appl. No.:
8/279899
Inventors:
Andrew J. Dannenberg - New York NY
Jayanta R. Chowdhury - New Rochelle NY
Jayanta R. Chowdhury - New Rochelle NY
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
Albert Einstein College of Medicine of Yeshiva University, a Division of
Yeshiva University - Bronx NY
Albert Einstein College of Medicine of Yeshiva University, a Division of
Yeshiva University - Bronx NY
International Classification:
A61K 3136, A61K 31195, A61K 31185, A61K 31095
US Classification:
514456
Abstract:
Based on the discovery that the human bilirubin/phenol UDP-glucuronosyltransferase ugt1 gene complex contains an electrophile responsive element and the knowledge that the rat NADP(H):quinone reductase gene contains an electrophile responsive element, agents which at a concentration of less than 50. mu. M double the quinone reductase specific activity of Hepa 1clc7 cells, e. g. , BHT and sulforaphane, are used for the prophylaxis or treatment of newborn jaundice.
Treatment Of Hpv Caused Diseases
US Patent:
7183316, Feb 27, 2007
Filed:
Mar 14, 2002
Appl. No.:
10/096819
Inventors:
Andrew J. Dannenberg - New York NY, US
Kotha Subbaramaiah - Flushing NY, US
Kotha Subbaramaiah - Flushing NY, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
A61K 31/34, A61K 31/451, A61K 31/38, A61K 31/60
US Classification:
514473, 514406, 514403, 514471, 514438, 514165
Abstract:
Human papillomavirus (HPV) protein expression is downregulated in patients infected with HPV by administration of PPARĪ³ ligand, selective inhibitor of cyclooxygenase-2 (COX-2), diaryl heterocycle, inhibitor of HPV protein from a natural source and/or certain non-steroidal anti-inflammatory drugs.